Argos Therapeutics (ARGS) Tops Q3 EPS by 3c

Argos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.32), $0.03 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $145.76 thousand versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance